India's Controller of Patents has turned down a compulsory license application by Lee Pharma to make a version of AstraZeneca's ($AZN) Onglyza, citing competing substitutes already in the market and patent terms, the Economic Times reported. Saxagliptin, sold under brand names Onglyza and Kombiglyze, treats Type 2 diabetes. On June 29, Hyderabad-based drugmaker Lee Pharma filed a compulsory license application in India for Onglyza, stating the DPP-4 inhibitor did not satisfy pricing criteria, while listing Dr. Reddy's Laboratories ($RDY), Teva Pharmaceutical Industries ($TEVA) and Zydus Cadila as potential customers, according to website SpicyIP. The Economic Times noted the India patent for Onglyza was granted to Bristol-Myers Squibb ($BMY) on April 30, 2007, and then transferred to AstraZeneca in a sale and is valid until March 5, 2016. The drug was potentially eligible for a compulsory license challenge under India's section 84(1) of the Patents Act 1970, the Economic Times said. Report